The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

Carhart-Harris, Robin L, Goodwin, Guy M·2017·Neuropsychopharmacology

DOI 10.1038/npp.2017.84

Cited by (702)

Items 101–200 of 702

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression
Facundo Carrillo, Mariano Sigman, Diego Fernández Slezak, Philip Ashton, Lily Fitzgerald, Jack Stroud, David Nutt, Robin Lester Carhart-Harris · 2018 · Journal of Affective Disorders
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review
Oliver Rumle Hovmand, Emil Deleuran Poulsen, Sidse Arnfred, Ole Jakob Storebø · 2023 · Journal of Psychopharmacology
Toward a contextual psychedelic-assisted therapy: Perspectives from acceptance and commitment therapy and contextual behavioral science
Luoma, Jason B., Sabucedo, Pablo, Eriksson, Johan, Gates, Nathan, Pilecki, Brian C. · 2019 · Journal of Contextual Behavioral Science
A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs
Marco Solmi, Chaomei Chen, Charles Dauré, Anne Buot, Michael Ljuslin, Vincent Verroust, Luc Mallet, Yasser Khazaal, Stéphane Rothen, Gabriel Thorens et al. · 2022 · European Neuropsychopharmacology
Psychedelic pleasures: An affective understanding of the joys of tripping
Frederik Bøhling · 2017 · International Journal of Drug Policy
Psychedelics and psychological flexibility – Results of a prospective web-survey using the Acceptance and Action Questionnaire II
Close, James B., Hajien, Eline C., Watts, Rosalind, Roseman, Leor, Carhart-Harris, Robin L. · 2020 · Journal of Contextual Behavioral Science
An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression
Sherry-Anne Muscat, Glenn Hartelius, Courtenay Crouch, Kevin W. Morin · 2021 · Frontiers in Psychiatry
Transcriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD
Joshua B. Burt, Katrin H. Preller, Murat Demirtaş, Jie Lisa Ji, John Harrison Krystal, Franz X. Vollenweider, Alan Anticevic, John D. Murray · 2021 · eLife
Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics
Glowacki, David R., Wonnacott, Mark D., Freire, Rachel, Glowacki, Becca R., Gale, Ella M., Pike, James E., de Haan, Tiu, Chatziapostolou, Mike, Metatla, Oussama · 2020 · Proceedings of the 2020 CHI Conference on Human Factors in Computing Systems
Artificial intelligence in drug development: reshaping the therapeutic landscape
Sarfaraz K. Niazi, Zamara Mariam · 2025 · Therapeutic Advances in Drug Safety
Lysergic Acid Diethylamide and Psilocybin for the Management of Patients with Persistent Pain: a Potential Role?
Andy Whelan, Mark I. Johnson · 2018 · Pain Management
An interpersonal neurobiology perspective on the mind and mental health: personal, public, and planetary well-being
Daniël J. Siegel, Chloe Drulis · 2023 · Annals of General Psychiatry
Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice
Tobias Buchborn, Taylor Lyons, Thomas Knöpfel · 2018 · Frontiers in Pharmacology
Motives for Classical and Novel Psychoactive Substances Use in Psychedelic Polydrug Users
Hannes Kettner, Natasha Leigh Mason, Kim P. C. Kuypers · 2019 · Contemporary Drug Problems
Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach
Igor Magaraggia, Zilla Kuiperes, Rudy Schreiber · 2021 · Neurobiology of Learning and Memory
Examining psychedelic-induced changes in social functioning and connectedness in a naturalistic online sample using the five-factor model of personality.
Weiss, Brandon, Nygart, Victoria, Pommerencke, Lis Marie, Carhart-Harris, Robin L., Erritzoe, David · 2021 · Frontiers in Psychology
Psychedelic medicalization, public discourse, and the morality of ego dissolution
Alex K. Gearin, Neşe Devenot · 2021 · International Journal of Cultural Studies
Serotonin, psychedelics and psychiatry
Robin Lester Carhart-Harris · 2018 · World Psychiatry
Potential benefits and harms: a review of poisonous mushrooms in the world
Mao-Qiang He, Meiqi Wang, Zuohong Chen, Wang-Qiu Deng, Tai‐Hui Li, Alfredo Vizzini, Rajesh Jeewon, Kevin D. Hyde, Rui-Lin Zhao · 2022 · Fungal Biology Reviews
Mindfulness meditation and psychedelics: potential synergies and commonalities
Holas, Paweł, Kamińska, Justyna · 2023 · Pharmacological Reports
The frontiers of new psychedelic therapies: A survey of sociological themes and issues
Timothy Andrews, Katie Wright · 2022 · Sociology Compass
Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer’s Disease and Related Dementias
Andrew H. Peterson, Emily A. Largent, Holly Fernandez Lynch, Jason H. Karlawish, Dominic A. Sisti · 2022 · AJOB Neuroscience
Brain dynamics predictive of response to psilocybin for treatment-resistant depression
J. Vohryzek, J. Cabral, Louis-David Lord, H. Fernandes, L. Roseman, D. Nutt, R. Carhart-Harris, G. Deco, M. Kringelbach · 2022 · bioRxiv
CE: Psychedelic-Assisted Therapy
Andrew Penn, Caroline G. Dorsen, Stephanie Hope, William E. Rosa · 2021 · AJN American Journal of Nursing
A phenomenology of subjectively relevant experiences induced by ayahuasca in upper Amazon vegetalismo tourism
Wolff, Tom John, Ruffell, Simon, Netzband, Nigel, Passie, Torsten · 2019 · Journal of Psychedelic Studies
A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers With PTSD and Depression
Shannon Dames, Pamela Kryskow, Crosbie Watler · 2022 · Frontiers in Psychiatry
Motives for the use of serotonergic psychedelics: A systematic review
Lukas Andreas Basedow, Sören Kuitunen‐Paul · 2022 · Drug and Alcohol Review
Relational Processes in Ayahuasca Groups of Palestinians and Israelis
Leor Roseman, Yiftach Ron, Antwan Saca, Natalie Lyla Ginsberg, Lisa Xiaolu Luan, Nadeem Karkabi, Rick Doblin, Robin Lester Carhart-Harris · 2021 · Frontiers in Pharmacology
Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model
McCrone, Paul, Fisher, Henry, Knight, Clare, Harding, Rebecca, Schlag, Anne K., Nutt, David J., Neill, Joanna C. · 2023 · Psychological Medicine
Classic Psychedelic Use and Mechanisms of Mental Health: Exploring the Mediating Roles of Spirituality and Emotion Processing on Symptoms of Anxiety, Depressed Mood, and Disordered Eating in a Community Sample
Lafrance, Adele, Strahan, Erin, Bird, Brian M., St. Pierre, Michelle, Walsh, Zach · 2021 · Journal of Humanistic Psychology
Who is the typical psychedelics user? Methodological challenges for research in psychedelics use and its consequences
Petter Grahl Johnstad · 2020 · Nordic Studies on Alcohol and Drugs
Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy
Michael Koslowski, Matthew W. Johnson, Gerhard Gründer, Felix Betzler · 2021 · Current Addiction Reports
Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice
Christopher W. Thomas, Cristina Blanco‐Duque, Benjamin J. B. Bréant, Guy M. Goodwin, Trevor Sharp, David M. Bannerman, Vladyslav V. Vyazovskiy · 2022 · Translational Psychiatry
Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review
Dominika Psiuk, Emilia Nowak, Natalia Dycha, Urszula Łopuszańska, Jacek Kurzepa, Marzena Samardakiewicz · 2022 · International Journal of Molecular Sciences
Translating Molecular and Neuroendocrine Findings in Posttraumatic Stress Disorder and Resilience to Novel Therapies
Jonathan M. DePierro, Lauren Lepow, Adriana Feder, Rachel Yehuda · 2019 · Biological Psychiatry
Psilocybin history, action and reaction: A narrative clinical review
Pravesh Sharma, Quang Anh Nguyen, Sadie J. Matthews, Erin Carpenter, Douglas B. Matthews, Christi A. Patten, Christopher Joseph Hammond · 2023 · Journal of Psychopharmacology
The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action
Daniela Dudysová, Karolína Janků, Michal Šmotek, Elizaveta Saifutdinová, Jana Kopřivová, Jitka Bušková, Bryce A. Mander, Martin Brunovský, Peter Zach, Jakub Korčák et al. · 2020 · Frontiers in Pharmacology
In vitro assays for the functional characterization of (psychedelic) substances at the serotonin receptor 5‐HT2AR
Eline Pottie, Christophe Pol Stove · 2022 · Journal of Neurochemistry
The Treatment of Substance Use Disorders: Recent Developments and New Perspectives
Annika Rosenthal, Claudia Ebrahimi, Friederike Wedemeyer, Nina Romanczuk‐Seiferth, Anne Beck · 2022 · Neuropsychobiology
The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression
Nicolas Garel, Jessica Drury, Julien Thibault Lévesque, Nathalie Goyette, Alexandre Lehmann, Karl Julian Looper, David Erritzøe, Shannon Dames, Gustavo Turecki, Soham Rej et al. · 2023 · Frontiers in Psychiatry
Monoamine Biosynthesis via a Noncanonical Calcium-Activatable Aromatic Amino Acid Decarboxylase in Psilocybin Mushroom
Michael Patrick Torrens-Spence, Chun‐Ting Liu, Tomáš Pluskal, Yin Kwan Chung, Jing‐Ke Weng · 2018 · ACS Chemical Biology
Dynamic sensitivity analysis: Defining personalised strategies to drive brain state transitions via whole brain modelling
Jakub Vohryzek, Joana Cabral, Francesca Castaldo, Yonatan Sanz Perl, Louis-David Lord, Henrique Miguel Fernandes, Vladimir Litvak A, Morten L. Kringelbach, Gustavo Deco · 2022 · Computational and Structural Biotechnology Journal
Psychedelic medicine: The biology underlying the persisting psychedelic effects
Kim P. C. Kuypers · 2019 · Medical Hypotheses
Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals
Anna Søndergaard, Martin Korsbak Madsen, Brice Ozenne, Sophia Armand, Gitte M. Knudsen, Patrick M. Fisher, Dea Siggaard Stenbæk · 2022 · Frontiers in Psychology
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling
Jack E. Henningfield, Marion A. Coe, Roland R. Griffiths, Sean J. Belouin, Ann M. Berger, Allison R. Coker, Sandra D. Comer, David J. Heal, Peter S. Hendricks, Charles David Nichols et al. · 2022 · Neuropharmacology
The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry
Joshua S. Kurtz, Neal Patel, Julian Lassiter Gendreau, Chenyi Yang, Nolan James Brown, Nick Bui, Bryce Picton, Mark Harris, Matthew J. Hatter, Ryan S. Beyer et al. · 2022 · Cureus
Psilocybin-Assisted Compassion Focused Therapy for Depression
Wendy T. M. Pots, Farid Chakhssi · 2022 · Frontiers in Psychology
An Improved, Practical, and Scalable Five-Step Synthesis of Psilocybin
Robert B. Kargbo, Alexander M. Sherwood, Poncho L. Meisenheimer, Gary Tarpley · 2020 · Synthesis
Validation of a new instrument for assessing attitudes on psychedelics in the general population
Marija Franka Žuljević, Ivan Buljan, Mia Leskur, Mariano Kaliterna, Darko Hren, Darko Duplančić · 2022 · Scientific Reports
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
Brandon Weiss, Leor Roseman, Bruna Giribaldi, David Nutt, Robin Lester Carhart-Harris, David Erritzøe · 2024 · International Journal of Mental Health and Addiction
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Johannes Gerardus Ramaekers, Johannes T. Reckweg, Natasha Leigh Mason · 2025 · American Journal of Psychiatry
Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine
David M. O’Shaughnessy, Ilana Berlowitz, Robin Rodd, Zóltan Sarnyai, Frances H. Quirk · 2021 · Therapeutic Advances in Psychopharmacology
Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways
Jitendra Kumar Sinha, Anchal Trisal, Shampa Ghosh, Saurabh Gupta, Dr. Krishna Kumar Singh, Sung Soo Han, Madhumita Mahapatra, Mosleh Mohammad Abomughaid, Ali M. Abomughayedh, Abdulmajeed G. Almutary et al. · 2024 · Ageing Research Reviews
A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder
Barsuglia, Joseph P., Polanco, Martin, Palmer, Robert, Malcolm, Benjamin J., Kelmendi, Benjamin, Calvey, Tanya · 2018 · Progress in Brain Research
Lifetime use of psychedelics is associated with better mental health indicators during the COVID-19 pandemic
Federico Cavanna, Carla Pallavicini, Virginia Milano, Juan Ignacio Cuiule, Rocco Di Tella, Pablo González, Enzo Tagliazucchi · 2021 · Journal of Psychedelic Studies
The renaissance in psychedelic research: What do preclinical models have to offer
Kevin Sean Murnane · 2018 · Progress in brain research
Entity encounters and the therapeutic effect of the psychedelic mystical experience
Anna Lutkajtis · 2021 · Journal of Evolutionary Psychology
LSD and ketanserin and their impact on the human autonomic nervous system
Sebastian Olbrich, Katrin H. Preller, Franz X. Vollenweider · 2021 · Psychophysiology
Serotonergic Psychedelics in Neural Plasticity
Kacper Łukasiewicz, Jacob J. Baker, Yi Zuo, Ju Lu · 2021 · Frontiers in Molecular Neuroscience
Psychedelics alter metaphysical beliefs
Christopher Timmermann, Hannes Kettner, Chris Letheby, Leor Roseman, Fernando E. Rosas, Robin Lester Carhart-Harris · 2021 · PsyArXiv (OSF Preprints)
Dissolving the self:Active inference, psychedelics, and ego-dissolution
Deane, George · 2020 · Philosophy and the Mind Sciences
Neuropsychiatric Disorders: Bridging the Gap Between Neurology and Psychiatry
Sanzida Taslim, Sujeet Shadmani, Abdul Rehman Saleem, Ajay Kumar, FNU Brahma, Narendar Blank, Muhammad Arsalan Bashir, Danya Ansari, Komal Kumari, Muhammad Usama Tanveer et al. · 2024 · Cureus · Retracted
Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI
Praachi Tiwari, Pasha A. Davoudian, Darshana Kapri, Ratna Mahathi Vuruputuri, Lindsay A. Karaba, Mukund Sharma, Giulia Zanni, Angarika Balakrishnan, Pratik Rajeev Chaudhari, Amartya Pradhan et al. · 2024 · Neuron
Pharmacokinetics of Psilocybin: A Systematic Review
Shakila Meshkat, Huda F. Al-Shamali, Argyrios Perivolaris, Trusha Tullu, Richard J. Zeifman, Yanbo Zhang, Lisa Burback, Olga Winkler, Andrew James Greenshaw, Muhammad Ishrat Husain et al. · 2025 · Pharmaceutics
Psychedelics and hypnosis: Commonalities and therapeutic implications
Clément E. Lemercier, Devin Blair Terhune · 2018 · Journal of Psychopharmacology
The Chronic Treatment With 5-HT2A Receptor Agonists Affects the Behavior and the BDNF System in Mice
Anton S. Tsybko, Tatiana V. Ilchibaeva, Elena Filimonova, Dmitry V. Eremin, Nina K. Popova, Vladimir S. Naumenko · 2020 · Neurochemical Research
Beating pain with psychedelics: Matter over mind?
Igor Elman, Amanda C. Pustilnik, David Borsook · 2021 · Neuroscience & Biobehavioral Reviews
Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation
Nadav Liam Modlin, Tammy M. Miller, James Rucker, Namik Kirlić, Molly Lennard-Jones, Danielle A. Schlosser, Scott T. Aaronson · 2023 · Journal of Affective Disorders
Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study
Maximillian J. Wood, Rosalind G. McAlpine, Sunjeev K. Kamboj · 2024 · Scientific Reports
Animal Behavior in Psychedelic Research
Anna U. Odland, Jesper Langgaard Kristensen, Jesper Tobias Andreasen · 2022 · Pharmacological Reviews
Potential Therapeutic Effects of Psilocybin: A Systematic Review
Dev B Goel, S. Zilate · 2022 · Cureus
Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics
Natasha Leigh Mason, Kim P. C. Kuypers · 2018 · Journal of Psychedelic Studies
Tripping over the other: Could psychedelics increase empathy?
Emily Blatchford, Stephen Jason Bright, Liam B. Engel · 2020 · Journal of Evolutionary Psychology
Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy
Agnieszka D. Sekula, Luke A. Downey, Prashanth Puspanathan · 2022 · Frontiers in Psychology
Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study
Kristjan Kaup, Madis Vasser, Kadi Tulver, Mari Munk, Juhan Pikamäe, Jaan Aru · 2023 · Frontiers in Psychiatry
Medical student attitudes and perceptions of psychedelic-assisted therapies
Irene Li, Rodney Fong, Molly M. Hagen, Burton Jared Tabaac · 2023 · Frontiers in Psychiatry
Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review
Noah Chisamore, Danica E. Johnson, Margery J.Q. Chen, Hilary Offman, David C. J. Chen-Li, Erica S. Kaczmarek, Zoe Doyle, Roger S. McIntyre, Joshua Daniel Rosenblat · 2024 · Journal of Psychiatric Research
5-HT 2A receptor activation normalizes stress-induced dysregulation of GABAergic signaling in the ventral tegmental area
Blake A. Kimmey, Alexey Ostroumov, John A. Dani · 2019 · Proceedings of the National Academy of Sciences
Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey
Valérie Bonnelle, William Smith, Natasha Leigh Mason, Mauro Cavarra, Pamela Kryskow, Kim P. C. Kuypers, Johannes Gerardus Ramaekers, Amanda Feilding · 2022 · British Journal of Pain
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression
Matthew B. Wall, Lysia Demetriou, Bruna Giribaldi, Leor Roseman, Natalie Ertl, David Erritzøe, David John Nutt, Robin Lester Carhart-Harris · 2025 · American Journal of Psychiatry
Beyond serotonin: newer antidepressants in the future
Gopalkumar Rakesh, Chi‐Un Pae, Prakash S. Masand · 2017 · Expert Review of Neurotherapeutics
Compassionate use of psychedelics
Adam Greif, Martin Šurkala · 2020 · Medicine Health Care and Philosophy
Epigenetic Echoes: Bridging Nature, Nurture, and Healing Across Generations
Blerida Banushi, Jemma R. Collova, Helen Milroy · 2025 · International Journal of Molecular Sciences
Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study
Luca Pellegrini, Naomi Anne Fineberg, Sorcha O'Connor, Ana Maria Frota Lisbôa Pereira de Souza, Kate Godfrey, Sara Reed, Joseph M. Peill, Mairead Healy, Cyrus Rohani-Shukla, Hakjun Lee et al. · 2025 · Comprehensive Psychiatry
Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice
Mario de la Fuente Revenga, Urjita H. Shah, Nima Nassehi, Alaina M. Jaster, Prithvi Hemanth, Salvador Sierra, Maƚgorzata Dukat, Javier González‐Maeso · 2021 · ACS Chemical Neuroscience
Psychedelics and mindfulness: A systematic review and meta-analysis
Chelsea Radakovic, Ratko Radaković, Guy Peryer, Jo‐Anne Geere · 2022 · Journal of Psychedelic Studies
Current and future directions of drug delivery for the treatment of mental illnesses
Parker R. Brewster, Saif Mohammad Ishraq Bari, Glenn M. Walker, Thomas A. Werfel · 2023 · Advanced Drug Delivery Reviews
Predictors and potentiators of psychedelic-occasioned mystical experiences
Sam Gandy · 2022 · Journal of Psychedelic Studies
Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review
James J Gattuso, Carey Wilson, Anthony John Hannan, Thibault Renoir · 2023 · Journal of Neurochemistry
Psychedelic-assisted therapies: The past, and the need to move forward responsibly
John Gardner, Adrian Carter, Kerry O’Brien, Kate Seear · 2019 · International Journal of Drug Policy
Effect of 5-HT2C receptor agonist and antagonist on chronic unpredictable stress (CUS) - Mediated anxiety and depression in adolescent Wistar albino rat: Implicating serotonin and mitochondrial ETC-I function in serotonergic neurotransmission
Wankupar Wankhar, Donkupar Syiem, Careen Liza Pakyntein, Daiahun Thabah, Shelareen Ediemi Sunn · 2020 · Behavioural Brain Research
The unique neural signature of your trip: Functional connectome fingerprints of subjective psilocybin experience
Hanna M. Tolle, Juan Carlos Farah, Pablo Mallaroni, Natasha Leigh Mason, Johannes Gerardus Ramaekers, Enrico Amico · 2023 · Network Neuroscience
Amazonian Medicine and the Psychedelic Revival: Considering the “Dieta”
David M. O’Shaughnessy, Ilana Berlowitz · 2021 · Frontiers in Pharmacology
Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders
Sheetal A. Raithatha, Jillian M. Hagel, Kaveh Matinkhoo, Lisa X Yu, David Press, Sarah G. Cook, Govinda Sharma, D. Dhananjaya, Glynnis Jensen, Jessica B. Lee et al. · 2023 · Journal of Medicinal Chemistry
Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach
Phil Wolfson, Gita Vaid · 2024 · Frontiers in Psychiatry
Induction of altered states of consciousness during Floatation-REST is associated with the dissolution of body boundaries and the distortion of subjective time
Helena Hruby, Stefan Schmidt, Justin S. Feinstein, Marc Wittmann · 2024 · Scientific Reports
Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience
Candace R. Lewis, Katrin H. Preller, Brittany B. Braden, Cory Riecken, Franz X. Vollenweider · 2020 · Biomedicines
Substances of abuse and the blood brain barrier: Interactions with physical exercise
Marta A. Małkiewicz, Andrzej Małecki, Michal J. Toborek, Arkadiusz Szarmach, Paweł Jan Winklewski · 2020 · Neuroscience & Biobehavioral Reviews
Acute behavioral and Neurochemical Effects of Novel N -Benzyl-2-Phenylethylamine Derivatives in Adult Zebrafish
Konstantin A. Demin, Olga V. Kupriyanova, Vadim A. Shevyrin, Ksenia A. Derzhavina, Nataliya A. Krotova, Nikita P. Ilyin, Tatiana O. Kolesnikova, David S. Galstyan, Yurii M. Kositsyn, Abubakar-Askhab S. Khaybaev et al. · 2022 · ACS Chemical Neuroscience
Bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate: a new crystalline form of psilacetin, an alternative to psilocybin as a psilocin prodrug
A.R. Chadeayne, James A. Golen, David R. Manke · 2019 · Acta Crystallographica Section E Crystallographic Communications